Hand-foot syndrome due to capecitabine

Surjushe, Amar; Vasani, Resham; Medhekar, Sudhir; Thakre, Minal; Saple, D. G.

doi:10.4103/0019-5154.55651

Cited by 15 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The report did not indicate the ethnicity of the patient. However, the accompanied clinical photographs indicate a patient with skin type IV-V [16].…”

Section: Resultsmentioning

confidence: 99%

Hyperpigmentation of the tongue, palms and soles: Rare side effect of capecitabine

Zekri¹,

Em²

2013

J Cancer Res Ther

View full text Add to dashboard Cite

Cutaneous side effects of capecitabine include hand foot syndrome which manifests as erythema, swelling and/or desquamation. We report a case on capecitabine treatment presenting with unusual hyperpigmentation of the tongue and skin of the palms and soles. This is a rare manifestation of capecitabine toxicity in darker skin patients. Clinicians and health care workers in oncology should be aware of this potential side effect.

show abstract

“…The report did not indicate the ethnicity of the patient. However, the accompanied clinical photographs indicate a patient with skin type IV-V [16].…”

Section: Resultsmentioning

confidence: 99%

Hyperpigmentation of the tongue, palms and soles: Rare side effect of capecitabine

Zekri¹,

Em²

2013

J Cancer Res Ther

View full text Add to dashboard Cite

show abstract

“…Various drugs implicated in the causation of HFS are infusional 5-flurouracil, capecitabine,[4] vinorelbine, liposomal doxorubicin, hydroxyurea, mercaptopurine, intravenous cyclosporine, methotrexate, cyclophosphamide, cytosine arabinoside, sunitinib, and sorefenib. The mechanism of HFS is still obscure.…”

Section: Discussionmentioning

confidence: 99%

Docetaxel-induced hand and foot syndrome in a patient with metastatic breast carcinoma

2013

View full text Add to dashboard Cite

Hand and foot syndrome (HFS) is a well-known complication of chemotherapeutic drugs given in a dose-dense manner. Our patient was a 52-year-old female with metastatic breast carcinoma on salvage chemotherapy regimen with docetaxel at a dose of 60 mg/m2. The patient had grade 3 HFS characterized by symmetrical, tender, and erythematous skin lesions over the palms and soles associated with dysesthesia necessitating interruption of treatment. She developed this syndrome at a much lower dose than previously described due to her altered hepatic function. An insight regarding this unique distressing side-effect and assessment of various contributing factors would help us identify and treat the patient at the earliest.

show abstract

“…FDA marketing label of 5-FU and capecitabine clearly warns that patients who are with homozygous and heterozygous mutation in the DPYD gene results in complete or partial absence of DPD activity and are at increased risk for the early onset toxicity and severe life-threatening or fatal adverse drug reactions like mucositis, hand-foot syndrome (HFS), diarrhoea, neutropenia and neurotoxicity [8]. HFS is also called palmar-plantar erythrodysesthesia characterized by severe skin changes like peeling, blisters, bleeding, and severe pain [9]. The major limitation of this polymorphism of being used as a predictive marker for toxicity is its lower minor allele frequency in different ethnic groups and only about 50% DPYD*2A allele carriers actually develop severe toxicities with 5-FU [10].…”

Section: Drug Metabolizing Enzymesmentioning

confidence: 99%

Single Nucleotide Polymorphisms as Biomarkers for Drug Response and Toxicity in the Management of Colorectal Cancer

Varma¹,

Mathaiyan²,

Shewade³

2018

J Pharmacogenomics Pharmacoproteom

View full text Add to dashboard Cite

The current methods of cancer treatment don't focus on the influence of interpatient genetic variations on the treatment outcomes. Genetic variations in the genes which are involved with drug metabolism and targets can affect treatment response and toxicity. In the recent time, many advances have been made to detect such candidate gene variations and use them as biomarkers in predicting the treatment outcomes in colorectal cancer (CRC). CRC remains one of the common causes of worldwide morbidity and mortality. In the last decade, many drugs have been approved including targeted therapies for the management of CRC which lead to improvement in the median survival and overall survival rate. However, there are significant variations in the response rate and toxicity among CRC patients with the current anti-cancer drugs. Interindividual response variations to chemotherapy can be influenced by several factors among them the genetic factor plays a key role. This emphasizes the need for the new genetic biomarkers which enable the selection of optimal drugs to benefit the patient care. This review focuses on single nucleotide polymorphisms which are known to affect the outcome of anticancer drugs used in the management of colorectal cancer.

show abstract

Hand-foot syndrome due to capecitabine

Cited by 15 publications

References 4 publications

Hyperpigmentation of the tongue, palms and soles: Rare side effect of capecitabine

Hyperpigmentation of the tongue, palms and soles: Rare side effect of capecitabine

Docetaxel-induced hand and foot syndrome in a patient with metastatic breast carcinoma

Single Nucleotide Polymorphisms as Biomarkers for Drug Response and Toxicity in the Management of Colorectal Cancer

Contact Info

Product

Resources

About